HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $77

Benzinga Newsdesk www.benzinga.com Positive 77.4%

Neg 0% Neu 0% Pos 77.4%

HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $70 to $77.